UCB SA announced positive results from its BE HEARD trials for BIMZELX in treating hidradenitis suppurativa, showing sustained symptom relief over three years. More than 90% of patients maintained HiSCR50 responses, with half achieving complete resolution of nodules and abscesses. Quality of life measures improved, with 38% reporting no impact from HS after three years. Long-term safety data remained consistent. The results, presented at a dermatology congress, highlight BIMZELX as a potential long-lasting treatment option. UCBJY stock is currently trading at $120.98 on the OTC Markets.

Read more at Nasdaq: UCB Reports 3 Year Data Showing Sustained Benefits Of BIMZELX In Hidradenitis Suppurativa